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Reply to the Editor:
We appreciate the comment and up-
date from Takagi and colleagues. They
previously reported the results of
a meta-analysis of controlled studies,
showing that preoperative statin use
was associated with reduced all-cause
mortality after cardiac surgery.1 At
this time, they added recently published
studies, including ours,2 in the meta-
analysis and showed that preoperative
statin therapy was associated with
a 33% reduction in postoperative mor-
tality (pooled odds ratio, 0.67; 95%
confidence interval, 0.54–0.83; P ¼
.0002), which supports a beneficial ef-
fect of preoperative statin use in pa-
tients undergoing cardiac surgery.
Their pooled analysis included 24,039
patients from 13 controlled studies.
However, the generalizability of their
finding is still not high.
Most patients included in their
pooled analysis underwent coronary ar-
tery bypass surgery. Statins have been
shown to be effective in the prevention
of major cardiac events in coronary ar-
tery disease.3,4 Perhaps most patients
undergoing coronary artery bypass sur-
gery are expected to be taking a statin
before surgery, although routine statin
therapy regardless of low-density lipo-
protein cholesterol level is still contro-
versial. All patients included in our
study had no coronary artery disease.2
Our study has indicated a potential ben-
efit of preoperative statin in patients un-
dergoing cardiac surgery without
coronary artery disease. However, the
study has limitations of observational
studies. A randomized controlled study
is necessary to confirm the finding.
To generalize the beneficial effect of
preoperative statin use in patients un-
dergoing cardiac surgery, further in-
vestigations are necessary in patients
without coronary artery disease or
those without hypercholesterolemia.
Minoru Tabata, MD, MPH
Department of Cardiovascular
Surgery
Sakakibara Heart Institute
Tokyo, Japan
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CORONARYARTERY BYPASS
VERSUS OFF-PUMP
CORONARYARTERY BYPASS
To the Editor:
We read with great interest the arti-
cle by Angelini and associates1 re-
garding effects of coronary arteryCardiovascular Surgery c September 2bypass grafting with cardiopulmonary
bypass (CABG-CPB) versus off-
pump coronary artery bypass (OP-
CAB) grafting on graft patency from
long-term (7-year) follow-up of 2 ran-
domized controlled trials (Beating
Heart Against Cardioplegic Arrest
Study [BHACAS] 1 and 2). The like-
lihood of graft occlusion was not dif-
ferent between OPCAB (10.6%) and
CABG-CPB (11.0%) groups (odds
ratio, 1.00; 95% confidence interval
[CI], 0.55–1.81; P > .99).1 Mean-
while, our previous meta-analysis2
of randomized controlled trials (not
including the study by Angelini and
collaborators1) demonstrated a statisti-
cally significant increase in venous
graft occlusion (risk ratio [RR],
1.28; 95% CI, 1.06–1.54; P ¼
.0094) and overall graft occlusion
(RR, 1.27; 95% CI, 1.03–1.56; P ¼
.0234) with OPCAB relative to
CABG-CPB in the random-effects
model. We herein updated the meta-
analysis,2 including the study by An-
gelini and colleagues.1
Our comprehensive search identi-
fied 7 studies reporting 3-month
graft patency. Pooled analysis of allFIGURE 1. Forest plot of venous graft occlusion risk among patients randomized to off-pump coro-
nary artery bypass (OPCAB) grafting versus coronary artery bypass grafting with cardiopulmonary by-
pass (CABG-CPB) in all studies (A) and studies reporting1-year patency (B). IV, Inverse variance; CI,
confidence interval.009
Reply to the Editor:
In this issue, Takagi and Umemoto1
report a meta-analysis of patency after
coronary artery bypass (CABG) and
off-pump CABG (OPCAB) that we
and others declined to conduct.2,3 We
have 4 comments on the appropriate-
ness of both their revised and original
analyses.4
The authors make the mistake that
we described in our article3—that is,
they assumed statistical independence
of multiple grafts in the same patients.
We reiterate that this ‘‘could seriously
undermine statistical inferences.’’3 In
our own primary patency analysis, ig-
noring the dependency between grafts
within patients would have narrowed
the confidence interval by 40%.
Underestimating the standard errors
by this amount would make all of their
pooled estimates not statistically sig-
nificant.
Meta-analysts should write a proto-
col in advance,5 including specifying
the planned analyses. Can Takagi and
Umemoto confirm that the subgroup
analysis by different conduit type
was prespecified? In the Beating Heart
Against Cardioplegic Arrest Study
(BHACAS) follow-up, the 2 groups
had very similar overall occlusion
rates, but the proportions of vein and
arterial grafts occluded in the OPCAB
compared with the CABG group hap-
pened to be in the directions observed
in the original meta-analysis.4 We had
no prior hypothesis that veins should
be more at risk of occlusion with OP-
CAB and concluded that our nonsig-
nificant findings arose by chance. Did
Takagi and Umemoto report the sub-
group analyses because it showed sta-
tistical significance, without a prior
intention to do so?
Although updating a meta-analysis
is always worthwhile, one should not
expect the addition of a single new re-
sult to overturn a previous conclusion
unless the new trial contributes an
overwhelming amount of new infor-
mation (depicted by the size of
a ‘‘blob’’ in a forest plot) or a substan-
tially different estimate (which might
cause concern about heterogeneity).
Neither was the case here.
Inspection of the blobs does, how-
ever, show that one trial contributes
most of the statistical weight.6 Interest-
ingly, the PRAGUE-4 trial reported pa-
tency findings for a similar number of
patients (255) as the BHACAS trials
(199), highlighting that the large weight
is due to a high rate of overall occlusion
(45%) compared with the other trials
(7%–17%). Meta-analysts need to
judge whether it makes sense to pool
data.5 We question whether the
PRAGUE trial should be pooled with
the others, even in the absence of statis-
tical heterogeneity and without obvious
major design differences between stud-
ies. Moreover, there are other important
sources of heterogeneity between trials,
Letters to the Editor7 studies demonstrated no statistically
significant difference in arterial graft
occlusion (RR, 1.01; 95% CI, 0.63–
1.60; P ¼ .98; P for heterogeneity
¼ .16) between OPCAB and
CABG-CPB but a statistically signifi-
cant increase in venous graft occlu-
sion (RR, 1.29; 95% CI, 1.08–1.54;
P ¼ .006; P for heterogeneity ¼
.98; Figure 1, A)1,3-7 and overall graft
occlusion (RR, 1.29; 95% CI, 1.00
[1.0028]–1.42; P ¼ .05 [.0465];
P for heterogeneity ¼ .27) with OP-
CAB relative to CABG-CPB in the
fixed-effects model. Two of the 7
studies stated 3-month graft patency,
whereas the remaining 5 studies re-
ported 1-year patency. In a sensitiv-
ity analysis, pooled analysis of the 5
studies reporting 1-year graft pa-
tency demonstrated no statistically
significant difference in arterial graft
occlusion (RR, 0.98; 95% CI, 0.58–
1.68; P ¼ .95; P for heterogeneity
¼ .36) and overall graft occlusion
(RR, 1.16; 95% CI, 0.97–1.40; P ¼
.11; P for heterogeneity ¼ .83) be-
tween OPCAB and CABG-CPB but
a statistically significant increase in
venous graft occlusion (RR, 1.27;
95% CI, 1.06–1.53; P ¼ .01; P for
heterogeneity ¼ .94; Figure 1, B)1,5-7
with OPCAB relative to CABG-
CPB in the fixed-effect model.
The results of our analysis suggest
that OPCAB may attenuate venous
graft patency over CABG-CPB. Four
of the 5 studies included in the sensi-
tivity analysis, however, had merely
1-year follow-up duration as con-
trasted with 7-year follow-up in the
study by Angelini and coworkers.1
Further long-term follow-up results
of randomized controlled trials are
needed to confirm our results.
Hisato Takagi, MD, PhD
Takuya Umemoto, MD, PhD
Shizuoka Medical Center
Department of Cardiovascular
Surgery
Shizuoka, JapanThe JournReferences
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